Ionis Pharmaceuticals shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $52 to $62.
Portfolio Pulse from Benzinga Newsdesk
Ionis Pharmaceuticals' stock (IONS) has seen an increase in its trading price following an upgrade from Neutral to Buy by B of A Securities, which also raised its price target for the stock from $52 to $62.

January 02, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals' stock has been upgraded by B of A Securities from Neutral to Buy, with a price target increase from $52 to $62, indicating a positive outlook on the stock.
The upgrade by B of A Securities from Neutral to Buy typically suggests a strong confidence in the company's future performance and is likely to instill positive sentiment among investors. The increase in the price target further reinforces this positive outlook, suggesting that the stock has the potential to rise to the new target price, thus likely leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100